Cure My Disease

Don't miss your cure!

 Log in / Sign up

Imfinzi under the microscope: how does it perform outside the lab?

NCT ID NCT04068168

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracked over 700 people in Korea who were already receiving the cancer drug Imfinzi (durvalumab) for lung or biliary tract cancer. The goal was to see how safe and effective the drug is in everyday medical practice, not just in strict clinical trials. Researchers monitored side effects and how long the drug kept the cancer from growing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER, BILIARY TRACT CANCER

Contacts and locations

Locations

  • Research Site

    Anyang-si, South Korea, South Korea

  • Research Site

    Bucheon-si, South Korea, South Korea

  • Research Site

    Busan, South Korea, South Korea

  • Research Site

    Changwon, South Korea, South Korea

  • Research Site

    Changwon-si, South Korea, South Korea

  • Research Site

    Cheonan, South Korea, South Korea

  • Research Site

    Chuncheon, South Korea, South Korea

  • Research Site

    Daegu, South Korea, South Korea

  • Research Site

    Daejeon, South Korea, South Korea

  • Research Site

    Goyang-si, South Korea, South Korea

  • Research Site

    Gwangju, South Korea, South Korea

  • Research Site

    Hwasun-gun, South Korea, South Korea

  • Research Site

    Iksan-si, South Korea, South Korea

  • Research Site

    Incheon, South Korea, South Korea

  • Research Site

    Jeju-do, South Korea, South Korea

  • Research Site

    Jeonju, South Korea, South Korea

  • Research Site

    Pohang-si, South Korea, South Korea

  • Research Site

    Seongnam-si, South Korea, South Korea

  • Research Site

    Seoul, South Korea, South Korea

  • Research Site

    Suwon, South Korea, South Korea

  • Research Site

    Uijeongbu-si, South Korea, South Korea

  • Research Site

    Wŏnju, South Korea, South Korea

  • Research Site

    Yangsan, South Korea, South Korea

  • Research Site

    Yongin-si, South Korea, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.